Citadel Advisors
WVE icon

Citadel Advisors’s Wave Life Sciences WVE Stock Holding History

Citadel Advisors’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.62M Sell
362,000
-430,300
-54% -$5.61M ﹤0.01% 5524
2025
Q4 		$13.5M Buy
792,300
+723,300
+1,048% +$7.35M ﹤0.01% 2848
2025
Q3 		$505K Buy
69,000
+36,100
+110% +$292K ﹤0.01% 9109
2025
Q2 		$214K Sell
32,900
-29,800
-48% -$197K ﹤0.01% 10529
2025
Q1 		$507K Buy
62,700
+4,600
+8% +$50.3K ﹤0.01% 8444
2024
Q4 		$719K Buy
58,100
+32,800
+130% +$438K ﹤0.01% 7758
2024
Q3 		$207K Buy
25,300
+9,600
+61% +$57.4K ﹤0.01% 10072
2024
Q2 		$78.3K Buy
15,700
+8,400
+115% +$47.9K ﹤0.01% 11240
2024
Q1 		$45K Buy
7,300
+2,800
+62% +$14K ﹤0.01% 12265
2023
Q4 		$22.7K Buy
+4,500
New +$24.1K ﹤0.01% 12515
2023
Q3 		– Sell
-12,700
Closed -$46.2K – 15231
2023
Q2 		$46.2K Buy
12,700
+400
+3% +$1.62K ﹤0.01% 11893
2023
Q1 		$53.3K Buy
12,300
+6,100
+98% +$27.9K ﹤0.01% 12074
2022
Q4 		$43.4K Buy
+6,200
New +$28.6K ﹤0.01% 12301
2022
Q1 		– Sell
-16,600
Closed -$52K – 14711
2021
Q4 		$52K Sell
16,600
-3,300
-17% -$13.7K ﹤0.01% 13231
2021
Q3 		$98K Sell
19,900
-3,400
-15% -$20.6K ﹤0.01% 12905
2021
Q2 		$155K Sell
23,300
-26,500
-53% -$173K ﹤0.01% 12470
2021
Q1 		$279K Buy
49,800
+31,900
+178% +$306K ﹤0.01% 11025
2020
Q4 		$141K Sell
17,900
-25,500
-59% -$214K ﹤0.01% 9992
2020
Q3 		$368K Buy
+43,400
New +$476K ﹤0.01% 7796
2020
Q2 		– Sell
-30,900
Closed -$290K – 10606
2020
Q1 		$290K Sell
30,900
-11,700
-27% -$99.7K ﹤0.01% 7404
2019
Q4 		$341K Buy
+42,600
New +$1.04M ﹤0.01% 7400

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Citadel Advisors's WVE Position: Q1 2026 in Review

Citadel Advisors increased its Wave Life Sciences (WVE) stake by 179% in Q1 2026, buying an estimated $18.4M and bringing the position to 2,202,856 shares worth $16M. The position accounts for ﹤0.01% of the portfolio, ranked #2611.

Citadel Advisors first reported a position in WVE in Q1 2018 and has held it in 25 quarters since. 230 funds tracked by Wall St. Rank hold WVE as of Q1 2026.

  • Citadel Advisors held 2,202,856 shares of Wave Life Sciences worth $16M as of Q1 2026.
  • Citadel Advisors bought 1,412,892 Wave Life Sciences shares in Q1 2026, an estimated $18.4M.
  • Wave Life Sciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2611 holding.
  • Citadel Advisors first reported a position in Wave Life Sciences in Q1 2018 and has held it in 25 quarters since.
  • 230 funds tracked by Wall St. Rank held Wave Life Sciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.